MedTrace Logo

Avutometinib and Defactinib in Diffuse Gastric Cancer

NCT06487221 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2025-11-04

No results posted yet for this study

Summary

The purpose of this study is to determine if the combination study treatment with avutometinib and defactinib will prolong life in participants, is effective in decreasing the size of the tumor(s), and if it is safe in subjects with diffuse-type stomach cancer.

Conditions

Interventions

DRUG

Avutometinib

3.2mg orally

DRUG

Defactinib

200 mg orally

Sponsors & Collaborators

  • Verastem, Inc.

    collaborator INDUSTRY

  • Ryan H. Moy, MD, PhD

    lead OTHER

Principal Investigators

  • Ryan Moy, MD, PhD · Columbia University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-28
Primary Completion
2028-11-30
Completion
2029-05-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06487221 on ClinicalTrials.gov